Premium
Association of fish oil supplement use with preservation of brain volume and cognitive function
Author(s) -
Daiello Lori A.,
Gongvatana Assawin,
Dunsiger Shira,
Cohen Ronald A.,
Ott Brian R.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.02.005
Subject(s) - neuropsychology , cognition , atrophy , brain size , neuroimaging , effects of sleep deprivation on cognitive performance , cognitive decline , psychology , hippocampus , cerebral atrophy , medicine , cohort , alzheimer's disease , neuropsychological assessment , brain structure and function , magnetic resonance imaging , disease , dementia , psychiatry , radiology
Abstract Objective The aim of this study was to investigate whether the use of fish oil supplements (FOSs) is associated with concomitant reduction in cognitive decline and brain atrophy in older adults. Methods We conducted a retrospective cohort study to examine the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative and indicators of cognitive decline. Older adults (229 cognitively normal individuals, 397 patients with mild cognitive impairment, and 193 patients with Alzheimer's disease) were assessed with neuropsychological tests and brain magnetic resonance imaging every 6 months. Primary outcomes included (1) global cognitive status and (2) cerebral cortex gray matter and hippocampus and ventricular volumes. Results FOS use during follow‐up was associated with significantly lower mean cognitive subscale of the Alzheimer's Disease Assessment Scale and higher Mini‐Mental State Examination scores among those with normal cognition. Associations between FOS use and the outcomes were observed only in APOE ε4–negative participants. FOS use during the study was also associated with less atrophy in one or more brain regions of interest.